Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Finerenone is safe and efficacious for treating patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D). Evidence on the use of finerenone in clinical practice is lacking. Objective: To describe demographic and clinical characteristics of early adopters of finerenone in the United States, according to sodium-glucose cotransporter 2 inhibitor (SGLT2i) use and urine albumin–creatinine ratio (UACR) levels. Methods: Multi-database, observational, cross-sectional study, using data from two US databases (Optum Claims and Optum EHR). Three cohorts were included: finerenone initiators with prior CKD-T2D, finerenone initiators with prior CKD-T2D and concomitant SGLT2i use, finerenone initiators with prior CKD-T2D stratified according to UACR. Results: In total, 1015 patients were included, 353 from Optum Claims and 662 from Optum EHR. Mean age was 72.0 and 68.4 years in Optum claims and EHR, respectively. Median eGFR was 44 and 44 ml/min/1.73 m2; and median UACR was 132 (28–698)/365 (74–1185.4) mg/g, in Optum Claims and EHR, respectively. 70.5/70.4% were taking renin-angiotensin system inhibitors, 42.5/53.3% SGLT2i. Overall, 9.0/6.3% of patients had baseline UACR <30 mg/g, 15.0/20.2% had UACR 30–300 mg/g, and 14.4/27.6% had UACR >300 mg/g. Conclusion: Current management of patients with CKD-T2D reflects use of finerenone independently from background therapies and clinical characteristics, suggesting implementation of therapeutic strategies based on different modes of action.
Supplementary Material
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease Introduction. Kidney Int. 98(4S), S1–S115 (2020).
2.
Thomas MC, Cooper ME, Zimmet P. Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. Nat. Rev. Nephrol. 12(2), 73–81 (2016).
3.
Rodriguez-Poncelas A, Garre-Olmo J, Franch-Nadal J et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study. BMC Nephrol. 14(1), 46 (2013).
4.
Wu B, Bell K, Stanford A et al. Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns—NHANES 2007–2012. BMJ Open Diab. Res. Care. 4(1), e000154 (2016).
• In the US, the prevalence of chronic kidney disease (CKD) in patients with Type 2 diabetes (T2D) was 38.3%.
5.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329(20), 1456–1462 (1993).
6.
Wheeler DC, James J, Patel D et al. SGLT2 inhibitors: slowing of chronic kidney disease progression in Type 2 diabetes. Diabetes Ther. 11(12), 2757–2774 (2020).
7.
Baran W, Krzemińska J, Szlagor M et al. Mineralocorticoid receptor antagonists – use in chronic kidney disease. Int. J. Mol. Sci. 22(18), 9995 (2021).
8.
Bakris GL, Agarwal R, Anker SD et al. Effect of finerenone on chronic kidney disease outcomes in Type 2 diabetes. N. Engl. J. Med. 383(23), 2219–2229 (2020).
9.
Pitt B, Filippatos G, Agarwal R et al. Cardiovascular events with finerenone in kidney disease and Type 2 diabetes. N. Engl. J. Med. 385(24), 2252–2263 (2021).
10.
Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43(6), 474–484 (2022).
•• Finerenone reduced the risk of CV and kidney outcomes in patients with T2D and CKD.
11.
EMA. Kerendia [product information website] (2022). www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf
12.
US FDA. Kerendia PI. Kerendia (finerenone) tablets. [Internet] (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
13.
Canada's Drug and Health Technology Agency. Finerenone [Internet] (2023). www.cadth.ca/finerenone
14.
NICE. Finerenone for treating chronic kidney disease in people with type 2 diabetes. NICE Technology Appraisal Guidance [TA877] (2023). www.nice.org.uk/guidance/ta877
15.
OHDSI. The Book of OHDSI: Observational Health Data Sciences and Informatics. OHDSI (2019). https://ohdsi.github.io/TheBookOfOhdsi/OhdsiAnalyticsTools.html#atlas
16.
Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother. Psychosom. 91(1), 8–35 (2022).
17.
Glasheen WP, Renda A, Dong Y. Diabetes Complications Severity Index (DCSI) – update and ICD-10 translation. J. Diabetes Complications 31(6), 1007–1013 (2017).
18.
Handelsman Y, Butler J, Bakris GL et al. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. J. Diabetes Complications 37(2), 108389 (2023).
19.
Heerspink HJ, Stefánsson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383(15), 1436–1446 (2020).
•• Among patients with CKD, dapagliflozin reduced the risk of CKD progression, regardless of the presence of T2D.
20.
Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. 380(24), 2295–2306 (2019).
21.
Chaudhuri A, Ghanim H, Arora P. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: a review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes. Metab. 24(3), 365–376 (2022).
22.
Terpening CM. Prevention of cardiovascular events in patients with chronic kidney disease. Ann. Pharmacother. 10600280231165774 (2023).
23.
Kolkhof P, Delbeck M, Kretschmer A et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 64(1), 69–78 (2014).
24.
Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J. Am. Coll. Cardiol. 75(4), 422–434 (2020).
25.
Grune J, Beyhoff N, Smeir E et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity. Hypertension 71(4), 599–608 (2018).
26.
Green JB, Mottl AK, Bakris G et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol. Dial. Transplant. 38(4), 894–903 (2023).
27.
González-Pérez A, Saéz ME, Vizcaya D, Lind M, García Rodríguez LA. Impact of chronic kidney disease definition on assessment of its incidence and risk factors in patients with newly diagnosed type 1 and type 2 diabetes in the UK: a cohort study using primary care data from the United Kingdom. Prim. Care Diabetes. 14(4), 381–387 (2020).
28.
Cunillera-Puértolas O, Vizcaya D, Cerain-Herrero MJ, Gil-Terrón N, Cobo-Guerrero S, Salvador-González B. Cardiovascular events and mortality in chronic kidney disease in primary care patients with previous type 2 diabetes and/or hypertension. A population-based epidemiological study (KIDNEES). BMC Nephrol. 23(1), 376 (2022).
29.
Kovesdy CP, Isaman D, Petruski-Ivleva N et al. Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study. Clin. Kidney J. 14(6), 1657–1664 (2021).
30.
Stengel B, Muenz D, Tu C et al. Adherence to the kidney disease: improving global outcomes ckd guideline in nephrology practice across countries. Kidney Int. Rep. 6(2), 437–448 (2021).
31.
Rossing P, Anker SD, Filippatos G et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 45(12), 2991–2998 (2022).
• In FIDELITY, the CV and renal benefits of finerenone were independent of treatment with SGLT2i.
32.
Folkerts K, Petruski-Ivleva N, Comerford E et al. Adherence to chronic kidney disease screening guidelines among patients withType 2 diabetes in a US Administrative Claims Database. Mayo Clin. Proc. 96(4), 975–986 (2021).
Information & Authors
Information
Published In
Copyright
© 2023 The Authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 12 May 2023
Accepted: 17 June 2023
Published online: 30 June 2023
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study. (2023) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2023-0076
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Csaba P. Kovesdy, Craig I. Coleman, Catherine B. Johannes, Anam M. Khan, Ryan Ziemiecki, J. Bradley Layton, David Vizcaya, Fangfang Liu, Nikolaus G. Oberprieler, Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States, Journal of Clinical & Translational Endocrinology, 10.1016/j.jcte.2026.100435, 44, (100435), (2026).
- Xiaoqing Deng, Yanyan Chen, Zhe Xu, Huan Wei, Yuqin Liao, Fangfang Liu, Alfredo E Farjat, Nikolaus G Oberprieler, Liming Chen, Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China, BMJ Open, 10.1136/bmjopen-2025-106126, 15, 12, (e106126), (2025).
- Yu Sun, Mingzhu Wang, Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease, International Urology and Nephrology, 10.1007/s11255-025-04456-8, 57, 8, (2567-2577), (2025).
- Csaba P. Kovesdy, Natalie Ebert, David Vizcaya, Michael Walsh, Mikhail N. Kosiborod, J. Bradley Layton, Ryan Ziemiecki, Catherine B. Johannes, Manel Pladevall-Vila, Patrick O. Gee, Nichole Jefferson, Annie Chicoye, Maria Lopes, Bishnu Bahadur Thapa, Gary Curhan, Luis Rangel, Mudit Bhartia, Fangfang Liu, Alfredo E. Farjat, Nikolaus G. Oberprieler, Change in Urine Albumin-Creatinine Ratio and Occurrence of Hyperkalemia in Patients Initiating Finerenone in the USA: A Cohort Study from the FOUNTAIN Platform, Nephron, 10.1159/000543923, 149, 7, (371-383), (2025).
- Nikolaus G. Oberprieler, Manel Pladevall-Vila, Catherine Johannes, J. Bradley Layton, Asieh Golozar, Martin Lavallee, Fangfang Liu, Maria Kubin, David Vizcaya, FOUNTAIN: a modular research platform for integrated real-world evidence generation, BMC Medical Research Methodology, 10.1186/s12874-024-02344-w, 24, 1, (2024).
- Susanne B. Nicholas, Ricardo Correa-Rotter, Nihar R. Desai, Lixin Guo, Sankar D. Navaneethan, Kevin M. Pantalone, Christoph Wanner, Stefanie Hamacher, Samuel T. Fatoba, Andrea Horvat-Broecker, Antonio Garreta-Rufas, Alain Gay, Martin Merz, David C. Wheeler, First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting, Journal of Nephrology, 10.1007/s40620-024-02070-y, 37, 8, (2223-2232), (2024).
- Atsuhisa Sato, Daloha Rodriguez-Molina, Kanae Yoshikawa-Ryan, Satoshi Yamashita, Suguru Okami, Fangfang Liu, Alfredo Farjat, Nikolaus G. Oberprieler, Csaba P. Kovesdy, Keizo Kanasaki, David Vizcaya, Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform, Journal of Clinical Medicine, 10.3390/jcm13175107, 13, 17, (5107), (2024).
- Yu. Sh. Khalimov, G. V. Semikova, Yu. A. Shutova, Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use, Diabetes mellitus, 10.14341/DM13113, 27, 1, (93-103), (2024).
- Wenmin Chen, Lingqian Zheng, Jiali Wang, Yongda Lin, Tianbiao Zhou, Overview of the safety, efficiency, and potential mechanisms of finerenone for diabetic kidney diseases, Frontiers in Endocrinology, 10.3389/fendo.2023.1320603, 14, (2023).